Evidence map›Paper›PMID 40730273›Full record

ArticleAnnals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology2025

Food allergy clinical course in children and adolescents treated with dupilumab for atopic dermatitis.

Alexander G Emerson, Matthew S Krantz, Rachel G Robison

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Emerging Paediatric Uses of Dupilumab Beyond Approvals.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026
    Review
  3. Update on biologic and small molecules treatments in pediatric allergic diseases.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alexander G EmersonDivision of Pediatric Allergy, Immunology, & Pulmonary Medicine, Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, Tennessee; Division of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Matthew S KrantzDivision of Allergy, Pulmonary and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, Tennessee.
Rachel G RobisonDivision of Pediatric Allergy, Immunology, & Pulmonary Medicine, Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: rachel.g.robison@vumc.org.

Funding

A Translational Bioinformatics Approach for Phenotyping and Genetic Risk of Severe Cutaneous Adverse Drug ReactionsK08AI185260 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Matthew Steven Krantz · 2025 to 2026
$373k
NIAID NIH HHS K08 AI185260NIAID NIH HHS L30 AI186122
6 · The paper itself

Abstract

backgroundDupilumab is a monoclonal antibody that inhibits type 2 inflammation through a blockade of interleukin-4 receptor alpha. It is approved for a number of atopic conditions; however, the effect of dupilumab on food allergy has not been fully evaluated.

objectiveTo describe the effect of dupilumab use on the clinical course of food allergy in patients receiving dupilumab for comorbid atopic dermatitis.

methodsThis retrospective study reviewed electronic medical records of children with food allergy at a single, tertiary care center receiving dupilumab for the treatment of atopic dermatitis. Food allergy testing, including skin prick test (SPT) and specific IgE (sIgE), and the outcomes of oral food challenges undertaken during routine clinical care were reviewed.

resultsA total of 60 children from 6 months to 18 years of age were included. Linear regression for percent change in measurement by months on dupilumab revealed that sIgE decreased by 0.6% (95% CI -0.8% to -0.4%, P < .001) for each additional month of treatment whereas SPT did not differ (0.1% [95% CI -0.6% to 0.7%], P = .8). Oral food challenge outcomes in this cohort were similar to previously published cohorts (76% pass rate) undergoing food challenges in a real-world setting irrespective of dupilumab use.

conclusionPatients with food allergy receiving dupilumab have greater decreases in sIgE with longer duration of dupilumab treatment whereas SPT seems to be more stable. This suggests that substantial decreases in SPT size over time may be a better correlate of clinical changes in food allergy compared with sIgE in patients with food allergy receiving dupilumab.

Indexed as

Antibodies, Monoclonal, HumanizedDermatitis, AtopicFood HypersensitivityAdolescentChildChild, PreschoolFemaleHumansImmunoglobulin EInfantInterleukin-4 Receptor alpha SubunitMaleRetrospective StudiesSkin TestsTreatment OutcomeAntibodies, Monoclonal, HumanizeddupilumabImmunoglobulin EInterleukin-4 Receptor alpha Subunit

Identifiers

PMID40730273
PMCPMC12609014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.